2. Academic Validation
  3. Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration

Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration

  • Bioorg Med Chem. 2023 Sep 7;92:117425. doi: 10.1016/j.bmc.2023.117425.
Michaela R Jacobs 1,  Jennifer E Olivero 2,  Hyun Ok Choi 3,  Chun-Peng Liao 4,  Boris A Kashemirov 5,  Jonathan E Katz 6,  Mitchell E Gross 7,  Charles E McKenna 8
Affiliations

Affiliations

  • 1 Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: [email protected].
  • 2 Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: [email protected].
  • 3 Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, CA 90064, USA. Electronic address: [email protected].
  • 4 Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, CA 90064, USA. Electronic address: [email protected].
  • 5 Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: [email protected].
  • 6 Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, CA 90064, USA; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: [email protected].
  • 7 Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, CA 90064, USA; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: [email protected].
  • 8 Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: [email protected].
PMID: 37544256 DOI: 10.1016/j.bmc.2023.117425
Abstract

Monoamine oxidases (MAOA/MAOB) are enzymes known for their role in neurotransmitter regulation in the central nervous system (CNS). Irreversible and non-selective MAO inhibitors (MAOi's) were the first class of antidepressants, thus subsequent work on drugs such as the selective MAOA inhibitor clorgyline has focussed on selectivity and increased CNS penetration. MAOA is highly expressed in high grade and metastatic prostate Cancer with a proposed effect on prostate Cancer growth, recurrence, and drug resistance. A Phase II Clinical Trial has demonstrated the therapeutic effects of the irreversible nonselective MAOi phenelzine for prostate Cancer. However, neurologic adverse effects led to early withdrawal in 25% of the enrolled patient-population. In this work, we revised the clorgyline scaffold with the goal of decreasing CNS penetration to minimize CNS-related side effects while retaining or enhancing MAOA inhibition potency and selectivity. Using the known co-crystal structure of clorgyline bound with FAD co-factor in the hMAOA active site as a reference, we designed and synthesized a series of compounds predicted to have lower CNS penetration (logBB). All synthesized derivatives displayed favorable drug-like characteristics such as predicted Caco-2 permeability and human oral absorption, and exhibited highly selective hMAOA binding interactions. Introduction of an HBD group (NH2 or OH) at position 5 of the phenyl ring clorgyline resulted in 3x more potent hMAOA inhibition with equivalent or better hMAOB selectivity, and similar prostate Cancer cell cytotoxicity. In contrast, introduction of larger substituents at this position or at the terminal amine significantly reduced the hMAOA inhibition potency, attributed in part to a steric clash within the binding pocket of the MAOA active site. Replacement of the N-methyl group by a more polar, but larger 2-hydroxyethyl group did not enhance potency. However, introduction of a polar 2-hydroxy in the propyl chain retained the highly selective MAOA inhibition and Cancer cell cytotoxicity of clorgyline while reducing its CNS score from 2 to 0. We believe that these results identify a new class of peripherally directed MAOIs that may allow safer therapeutic targeting of MAOA for a variety of anti-cancer and anti-inflammatory indications.

Keywords

Clorgyline; Drug design; Enzalutamide; MAOI; Neurotoxicity; Prostate cancer; SAR; Synthesis.

Figures
Products